Edition:
United States

GlycoMimetics Inc (GLYC.OQ)

GLYC.OQ on NASDAQ Stock Exchange Global Market

23.35USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$23.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
173,001
52-wk High
$26.05
52-wk Low
$3.83

Chart for

About

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment... (more)

Overall

Beta: 3.13
Market Cap(Mil.): $801.79
Shares Outstanding(Mil.): 34.34
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.80 16.52
EPS (TTM): -- -- --
ROI: -- -0.65 36.19
ROE: -- -3.21 17.38

BRIEF-Glycomimetics Enters Agreement With Hovon To Initiate Study Startup Activities For Planned Clinical Trial Of GMI-1271 And Decitabine

* GLYCOMIMETICS ENTERS INTO AGREEMENT WITH HOVON TO INITIATE STUDY STARTUP ACTIVITIES FOR PLANNED CLINICAL TRIAL OF GMI-1271 AND DECITABINE IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE UNFIT FOR CHEMOTHERAPY

Feb 08 2018

BRIEF-GlycoMimetics qtrly loss per share $‍0.24

* Glycomimetics reports program updates and third quarter 2017 results

Nov 08 2017

BRIEF-GlycoMimetics says files for mixed shelf of upto $250 mln

* GlycoMimetics Inc says files for mixed shelf of upto $250.0 million - SEC filing‍​ Source text: (http://bit.ly/2xOoKE6) Further company coverage:

Sep 28 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $129.91 0.00
Novartis AG (NOVN.S) CHF79.56 -0.42
Pfizer Inc. (PFE.N) $35.74 -0.02
Merck & Co., Inc. (MRK.N) $54.57 +0.02
Roche Holding Ltd. (ROG.S) CHF222.00 -1.30
Roche Holding Ltd. (RO.S) CHF225.20 -1.20
Bayer AG (BAYGn.DE) €98.38 -0.06
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates